

Drugs and pharmaceuticals—Cont.

- Costs/prices, Bill C-22 increasing, \$650-660 million...—Cont.
 New drugs, persistent rise over time, 14:62; 15:42, 80-1
 Physicians' fees, capping, comparison, 6:77
 Restrictive Trade Practices Commission, "green book" study, 6:48-9, 57
 Single-source drugs, 6:57
 Social costs, factoring, 11:49; 12:31
Stop Multinationals Monopolizing Medicine, magazine article, 94% projected price increase, 15:82-3
 Studies, tabling, 1:16, 19
 Tagamet/cimetidine example, 1:44-5; 5:30; 6:19-20, 28, 40, 75-6, 81-2; 7:15-6; 8:56; 10:8; 13:19; 14:42
 United States comparison, 3:18, 58-9; 15:56, 84
 See also Drugs and pharmaceuticals—Costs/prices, Insurance rates
 Walker, Michael, quotation, 8:62
 Welfare programs, effect, 6:62, 67-8
 See also Disabled and handicapped; Drugs and pharmaceuticals—Provinces; Group Surgical-Medical Insurance Plan
 Currently on market, Bill C-22 not covering, 8:26
 Cyclosporin, price, benefits, etc., 13:6-9, 11, 15
 Drug compliance, defining, 9:46
 L-Dopa, 6:41; 14:15
 National Health and Welfare Department, Health Protection Branch, testing/clearance process, 3:18, 24; 5:11, 23-4; 10:32; 12:38; 13:17; 15:90-1
 See also Drugs and pharmaceuticals—Usage
 Orphan drugs, 15:73
 Drug Prices Review Board review, 5:28
 Policy objectives, 5:11
 Product characteristics, no close substitutes, 5:10
 Provinces, Bill C-22, costs increasing, bulk purchasing, pharmacare programs affected, etc., 1:26-7, 29; 9:25-6, 28-9; 11:77; 12:24, 59, 69; 14:55; 15:21-3, 58, 98; 16:16
 Drug prices review boards, establishing, proposal, 6:51, 59-60
 Economic disparity, Bill C-22 promoting, 6:55, 66
 Federal government \$100 million off-set plans, etc., 1:14-5, 18-9, 32; 3:6, 11, 16, 35-6; 6:40, 52-4, 65-6; 9:25, 27-8; 10:24-5; 11:22, 56, 71; 12:21, 69; 14:9, 11; 15:22, 59, 82; 16:14-6
 Manitoba, \$14 million savings, etc., 15:85-6, 88, 93-5
 Negotiating power, 6:59-60; 11:50
 Nova Scotia, Health minister estimate, 9:27; 11:57-8; 12:21, 56; 14:11, 38
 Ontario, \$35 million estimate, 11:52, 57; 12:56
 Possible Costs and Savings to the Provinces of Bill C-22, paper, 1:15
 Product selection, reducing, 6:76, 82
 Saskatchewan, \$8-12 million estimate, 11:70; 12:21, 56
 Pricing, market forces, etc., 11:72-3
 Purchasing from abroad, Eastman report recommendation, 14:61, 72
 Side-effects see Generic drugs
 Single-source, generic copying, 3:19, 59-60; 6:70
 See also Drugs and pharmaceuticals—Costs/prices
 Tagamet/cimetidine, 1:28-9; 5:30
 Compulsory licensing, effect, 3:30
 Development cost, 14:41
 Health care savings, 11:40, 47-8; 14:36-7, 44
 Origin, 14:41
 Ranitidine, comparison, 6:36
 Zantac, comparison, 6:47
 See also Drugs and pharmaceuticals—Costs/prices; Generic drugs, Intellectual property
 Timolol, 14:15

Drugs and pharmaceuticals—Cont.

- United States
 Drug Export Amendments Act, 1986, free trade negotiations threat, 8:43
 Nightmare situation developing, 8:68
 See also Drugs and pharmaceuticals—Costs/prices—Valium; Generic drugs
 Usage, native groups, ethnic groups, etc., 15:44-6, 53
 National Health and Welfare Department, Health Protection Branch study proposal, 15:74-5
 Valium, United States origin, 12:11
 See also Brand name drugs; Cardiovascular medicine; Diabetes; Drug plans; Generic drugs; Health care—Hospitals; Multiple Sclerosis Society of Ottawa-Carleton; Prescription drugs
- Drugs and pharmaceuticals industry**
 Assembly/branch plant operation criticism, 9:19, 49; 11:5
 Background, 6:51-2
 Balance of payments deficit, 13:37, 40-1
 Canadian ownership, preserving, 11:5; 14:24; 15:66-8
 Competition, price control, etc., 6:18; 7:6-8, 14; 8:26, 48; 12:65-6, 73; 13:18-9; 14:55; 15:72
 Compulsory licensing, effect, 8:61; 9:12; 11:6; 14:58, 61; 15:27
 Consumer movements, international, similiar legislation requesting, 11:56
 Haddad comment, 12:9, 67; 14:23
 See also Drugs and pharmaceuticals industry—Montreal—Research and development
 Domestic, taxpayer funding/foreign marketing, 15:16
 Educational activities, 15:14
 Employees, key to success, 11:14
 Fine chemicals manufacturing potential, research and production, tying, international examples, etc., 1:21-2; 3:8; 11:6, 12; 13:44; 15:87
 Production costs, Torcan estimates, 15:88
 See also Drugs and pharmaceuticals industry—Transfer pricing issue
 Growth, 1:15; 3:9; 15:72
 Baby boom factor, 12:66
 Industrial strategy, 13:38-40, 44
 Legislation, Bill C-22 impact, 3:7; 15:31-2, 34
 Market environment, United States drug industry view, 6:50
 Marketing practices, India example, 9:41
 Montreal, Quebec, 10:5-6, 19
 Biotechnology centre, 10:11-2
 Compulsory licensing, effect, 10:12-3
 Delmar Chemicals Division of Canada Packers Inc., fine chemicals plant expansion, 10:17
 Research and development commitments, 10:8, 11, 13-4, 17
 Patents, tailoring, 5:10
 Profits, 3:6; 8:20-1; 15:72
 Fair profits, determining, 6:31, 59; 11:16
 Research and development, no impact, Eastman report findings, 1:22-4; 14:58-9, 64
 Promotion expenditures to sales, ratio, 5:11
 Drug Prices Review Board assessing, proposal, 8:9
 Quebec, Bill C-22 stimulating, 12:17
 See also Drugs and pharmaceuticals industry—Montreal, Quebec
 Research and development, 14:7; 15:28
 Benefits, Bill C-22, 5:24-5, 43; 8:54; 12:5-7, 13-4; 13:7, 9, 13-4, 18, 20-1, 46; 14:58; 15:7-8
 Centralization, head office country, 10:42; 11:9-12, 14, 43-4, 64; 12:71; 13:27, 43; 14:64, 76; 15:25, 37, 74, 87
 Economist magazine article, 13:27-8
 Climate, Eastman observations, etc., 3:49, 64; 10:38; 12:32; 13:27; 15:87